Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.

Maira-Litrán T, Kropec A, Goldmann DA, Pier GB.

Infect Immun. 2005 Oct;73(10):6752-62. Erratum in: Infect Immun. 2005 Nov;73(11):7789.

2.

Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.

Maira-Litrán T, Bentancor LV, Bozkurt-Guzel C, O'Malley JM, Cywes-Bentley C, Pier GB.

PLoS One. 2012;7(9):e43813. doi: 10.1371/journal.pone.0043813. Epub 2012 Sep 6.

3.

Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.

Gening ML, Maira-Litrán T, Kropec A, Skurnik D, Grout M, Tsvetkov YE, Nifantiev NE, Pier GB.

Infect Immun. 2010 Feb;78(2):764-72. doi: 10.1128/IAI.01093-09. Epub 2009 Nov 30.

4.

Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine.

Cerca N, Jefferson KK, Maira-Litrán T, Pier DB, Kelly-Quintos C, Goldmann DA, Azeredo J, Pier GB.

Infect Immun. 2007 Jul;75(7):3406-13. Epub 2007 Apr 30.

5.

The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.

Kelly-Quintos C, Kropec A, Briggs S, Ordonez CL, Goldmann DA, Pier GB.

J Infect Dis. 2005 Dec 1;192(11):2012-9. Epub 2005 Nov 1.

6.

Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.

Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB.

Clin Infect Dis. 2012 Nov;55(9):1188-97. doi: 10.1093/cid/cis624. Epub 2012 Jul 17.

7.

Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice.

Skurnik D, Merighi M, Grout M, Gadjeva M, Maira-Litran T, Ericsson M, Goldmann DA, Huang SS, Datta R, Lee JC, Pier GB.

J Clin Invest. 2010 Sep;120(9):3220-33. doi: 10.1172/JCI42748. Epub 2010 Aug 25.

8.

Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.

Pozzi C, Wilk K, Lee JC, Gening M, Nifantiev N, Pier GB.

PLoS One. 2012;7(10):e46648. doi: 10.1371/journal.pone.0046648. Epub 2012 Oct 15.

9.

A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.

Lu X, Skurnik D, Pozzi C, Roux D, Cywes-Bentley C, Ritchie JM, Munera D, Gening ML, Tsvetkov YE, Nifantiev NE, Waldor MK, Pier GB.

MBio. 2014 Mar 25;5(2):e00974-14. doi: 10.1128/mBio.00974-14.

10.

Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates.

Park S, Gerber S, Lee JC.

Infect Immun. 2014 Dec;82(12):5049-55. doi: 10.1128/IAI.02373-14. Epub 2014 Sep 22.

11.

Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens.

Cywes-Bentley C, Skurnik D, Zaidi T, Roux D, Deoliveira RB, Garrett WS, Lu X, O'Malley J, Kinzel K, Zaidi T, Rey A, Perrin C, Fichorova RN, Kayatani AK, Maira-Litràn T, Gening ML, Tsvetkov YE, Nifantiev NE, Bakaletz LO, Pelton SI, Golenbock DT, Pier GB.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):E2209-18. doi: 10.1073/pnas.1303573110. Epub 2013 May 28.

13.
14.

Comparative antibody-mediated phagocytosis of Staphylococcus epidermidis cells grown in a biofilm or in the planktonic state.

Cerca N, Jefferson KK, Oliveira R, Pier GB, Azeredo J.

Infect Immun. 2006 Aug;74(8):4849-55.

15.

Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide.

Cerca N, Maira-Litrán T, Jefferson KK, Grout M, Goldmann DA, Pier GB.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7528-33. Epub 2007 Apr 19.

16.

Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.

Fattom AI, Sarwar J, Basham L, Ennifar S, Naso R.

Infect Immun. 1998 Oct;66(10):4588-92.

17.

Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.

McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Döring G, Lee JC, Goldmann DA, Pier GB.

Science. 1999 May 28;284(5419):1523-7.

18.

Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections.

Bentancor LV, O'Malley JM, Bozkurt-Guzel C, Pier GB, Maira-Litrán T.

Infect Immun. 2012 Feb;80(2):651-6. doi: 10.1128/IAI.05653-11. Epub 2011 Nov 21.

19.

Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection.

Kropec A, Maira-Litran T, Jefferson KK, Grout M, Cramton SE, Götz F, Goldmann DA, Pier GB.

Infect Immun. 2005 Oct;73(10):6868-76.

20.

Potential use of poly-N-acetyl-beta-(1,6)-glucosamine as an antigen for diagnosis of staphylococcal orthopedic-prosthesis-related infections.

Sadovskaya I, Faure S, Watier D, Leterme D, Chokr A, Girard J, Migaud H, Jabbouri S.

Clin Vaccine Immunol. 2007 Dec;14(12):1609-15. Epub 2007 Oct 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk